# Prime Editing **Entity class:** Method **Domain:** Genome Editing / Personalized Therapeutics **Doc Type:** Technology Node **Maturity:** Clinical-stage **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[research/Research Inferences|Research Inferences]] (INF-0330) ## Definition **Prime editing writes a specified DNA sequence at a chosen site without making a double-strand break.** A reverse transcriptase fused to a targeting protein copies the intended sequence from an attached guide RNA directly into the genome, so the edit is carried as a parameter rather than requiring a redesigned tool for each target. That property is what makes therapy development resemble software work: the molecule changes, the method does not. ## Platform position Prime editing is the technique behind the register's strongest platform-approval argument. An umbrella-of-umbrellas protocol covering seven urea cycle disorders under a single customizable prime-editing platform was discussed with the FDA under the [[wiki/Plausible Mechanism Framework|Plausible Mechanism Framework]], and reported in the *American Journal of Human Genetics* in 2026. Approving a method rather than a molecule is the change that makes n-of-one medicine economically possible; the same commentary cautions that an abbreviated path still depends on meeting evidentiary requirements ordinarily reserved for late-stage trials. ## Forward Capability Where [[wiki/Base Editing|base editing]] addresses single-letter changes, prime editing addresses insertions, deletions and replacements, which widens the share of pathogenic variants a single platform can reach. Combined with redosable [[wiki/Lipid Nanoparticle|lipid-nanoparticle]] delivery and designed enzymes, the therapeutic becomes a computationally specified artifact, and a sequence transmitted to a site near the patient could in principle be synthesized there rather than shipped. ## Open Questions - The first umbrella investigational new drug application covering multiple patient-specific guides under one protocol. - Editing efficiency in post-mitotic tissue, the condition that matters for neurons. - Delivery of the larger prime-editing machinery across the blood-brain barrier. ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0330 — Established.** Prime editing writes specified sequences without double-strand breaks, making the edit a parameter rather than a redesign. When the therapeutic is a string, therapy development becomes a software-like activity with software-like iteration speed. - **INF-0329 — Strongly indicated.** An umbrella-of-umbrellas protocol covering seven urea cycle disorders under one platform converts regulation from per-drug to per-method. Approving a method rather than a molecule is the change that makes n-of-one medicine economically possible. - **INF-0333 — Established.** The field's argument that the FDA pathway converts an economically unworkable model into a scalable clinical reality is being made by the people who built the editing tools. Practitioner advocacy shaping regulatory design is the normal mechanism by which capability becomes permitted. - **INF-0346 — Analytic.** When the enzyme is designed, the guide is a string, and delivery is a formulation, the whole therapeutic becomes a computationally specified artifact. The iteration loop for medicine begins to resemble the iteration loop for software, which changes its improvement rate. - **INF-0347 — Plausible.** A therapy specified as sequence data can be transmitted and synthesized near the patient rather than shipped. Manufacturing at the point of care is the logical endpoint of a fully digital therapeutic specification, and it makes distance irrelevant to treatment. ## Relationships - **technique_peer:** [[wiki/Base Editing|Base Editing]]. - **regulatory_vehicle:** [[wiki/Plausible Mechanism Framework|Plausible Mechanism Framework]] · [[wiki/United States Food and Drug Administration|United States Food and Drug Administration]]. - **delivery:** [[wiki/Lipid Nanoparticle|Lipid Nanoparticle]]. - **funder:** [[wiki/ARPA-H|ARPA-H]] (AEGIS consortium). - **cluster_home:** [[wiki/Real-Time Genetic Repair|Real-Time Genetic Repair]]. - **case_precedent:** [[wiki/Baby KJ|Baby KJ]] established the single-patient route that platform approval would generalize. - **ecosystem:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[collections/Neurotech|Neurotech]]. ## Sources - [Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform — American Journal of Human Genetics, 2026](https://www.cell.com/ajhg/fulltext/S0002-9297(26)00148-5) - [Considerations for the Use of the Plausible Mechanism Framework — Federal Register, 25 February 2026](https://www.federalregister.gov/documents/2026/02/25/2026-03713/considerations-for-the-use-of-the-plausible-mechanism-framework-to-develop-individualized-therapies) As of 23 October 2026.